published meta-analysis   sensitivity analysis   studies

Early convalescent plasma. in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25] 1.01[0.06; 16.25]CoV-Early (Gharbharan), 202210%416NAnot evaluable deathsdetailed resultsCoV-Early (Gharbharan), 2022 1.01 [0.06; 16.25] 1.01[0.06; 16.25]CoV-Early (Gharbharan), 202210%416NAnot evaluable hospitalizationdetailed resultsCoV-Early (Gharbharan), 2022 0.61 [0.28; 1.33] 0.61[0.28; 1.33]CoV-Early (Gharbharan), 202210%416NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-26 17:40 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 958 - roots T: 290